All samples were tested for the presence of anti-HEV IgM and IgG (Wantai). In the serologic positive GBS patients, serum/EDTA plasma, available stool and cerebrospinal fluid samples were tested

for HEVRNA (quantitative real-time PCR). HEV-ORF1 sequences were used for genotyping. Ferrostatin-1 An increased ratio of anti-HEV IgM antibodies was found in 10 GBS patients (5%) compared to 1 healthy control (0.5%) (O R 10.5, CI 1.3-82.5; p = 0.010). HEV RNA was detected in serum from 3 of these patients and additionally in faeces from 1 patient. HEV-ORF1 phylogenetic analysis characterised two samples as non related genotype 3 strains. 70% of anti-HEV IgM positive patients had mildly increased ALT (median 70 IU/L), range 26-921). All CSF samples were negative for HEV RNA, excluding an infectious polyradiculoneuropathy. The presence of anti-HEV IgM in GBS patients was not related to age, gender, disease severity or out-come after 6 months. IgM anti-ganglioside GM1 antibodies were detected in one anti-HEV IgM positive patient. Anti-HEV IgG was demonstrated in 92 (46%) patients compared to 77 (38%) healthy controls (O R 1.4, CI 0.9-2.0; p=0.130). see more Patients

with anti-HEV IgG antibodies were older (median age 60, IQR 44-69) than patients without these antibodies (median age 44, IQR 30-59) (p<0.001) and initially more severely affected (higher GBS disability score at entry) (p=0.003). This study indicates that HEV may be a new type of infection preceding GBS. In the Netherlands, 5% of patients with GBS have associated acute hepatitis E. Further research is required to determine by what mechanism HEV may trigger GBS and Benzatropine if HEV infections also precede

the onset of GBS in other geographical areas. Disclosures: Suzan D. Pas – Grant/Research Support: the Virgo consortium, funded by the Dutch government (FES0908), the Netherlands Genomics Initiative (NGI) project number 050-060-452, the European Community Seventh Framework Programme (FP7/2007-2013) under project EMPERIE (grant agreement no. 223498) Harry Dalton – Consulting: GSK, Wantai, Aptalis; Speaking and Teaching: Merck The following people have nothing to disclose: Bianca van den Berg, Richie G. Madden, Jeremy G. Hunter, Anne P. Tio-Gillen, Annemiek A. van der Eijk, Bart C. Jacobs “
“Aim:  miRNAs have been found to regulate gene expression at a posttranscriptional level in cells. Studies have shown that expression of miRNAs is tissue-specific and developmental stage-specific. The mechanism behind this could be explained by miRNA pathways. Methods:  We introduce the identification of miRNAs from two human fetal liver cDNA libraries by a cloning protocol. The miRNAs detected were then analyzed in a chorionic villus tissue and four liver tissues using real-time polymerase chain reaction. Results:  After sequencing and database searching, a total of 42 miRNAs in two fetal livers were detected.